comparemela.com

Latest Breaking News On - Nasdaq hearings panel - Page 13 : comparemela.com

Scinai Immunotherapeutics : The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance - Form 6-K

Scinai Immunotherapeutics : The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Vivos Therapeutics : Material Event - Form 8-K

Item 8.01 Other Information As previously reported, on November 30, 2023, a Nasdaq Hearings Panel provided Vivos Therapeutics, Inc. until March 19, 2024 to regain compliance.

Mesa Air : Failure to Satisfy Listing Rule - Form 8-K

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.